BioSpace News Archive

Business

Inauguration Address of New President and CEO of PHC Holdings Corporation

PHC Holdings Corporation has announced that Michael Kloss has taken up the position of President and CEO of PHCHD effective April 1, 2019.

April 1, 2019
·
3 min read
Deals

Arteaus Therapeutics Sells Emgality Royalty to Royalty Pharma for $260 Million

Royalty Pharma and Arteaus Therapeutics announced that Arteaus has sold its royalty interest on future global net sales of Eli Lilly and Company’s Emgality, an anti-CGRP antibody for the prevention of migraine, to Royalty Pharma for $260 million.

April 1, 2019
·
3 min read
Drug Development

Terns Pharmaceuticals to Present Preclinical Data on Two Lead Programs at the European Association for the Study of the Liver (EASL) Annual Meeting 2019

TERN-101 Demonstrated Potency as an Agonist of FXR Nuclear Hormone Receptor

April 1, 2019
·
4 min read
Nordion and BRIT Collaborate to Bring Cobalt-60 from India to Global Markets

Nordion (Canada) Inc. announces the purchase of Cobalt-60 from the Board of Radiation and Isotope Technology, a unit of the Government of India Department of Atomic Energy, for distribution to Europe.

April 1, 2019
·
2 min read
Pharm Country

Medigate Expands Award-Winning Medical Device Security and Asset Management Platform to Include General IoT Devices

Solution addresses the growing need for one IoT security solution that discovers, manages and secures all devices on a Health Delivery Organization’s network

April 1, 2019
·
2 min read
Drug Development

Exicure to Present at the AACR Annual Meeting 2019

Data presented in collaboration with Celldex show that Exicure’s technology leads to a more potent anti-tumor response when combined with Celldex’s CDX-301

April 1, 2019
·
4 min read
Policy

Vizient Submits Recommendation to CMS for Changes to Hospital Star Ratings Methodology

In response to the Centers for Medicare and Medicaid Services request for public input on the methodology of the Overall Hospital Quality Star Rating on the Hospital Compare website, Vizient has submitted a detailed proposal for a more clinically grounded approach for the ratings.

April 1, 2019
·
2 min read
Drug Development

BerGenBio: Bemcentinib in Combination With low-dose Chemotherapy Achieves Efficacy Endpoint in AML Patients

Phase II trial evaluating bemcentinib in combination with low-dose chemotherapy in AML patients unfit for intensive therapy

April 1, 2019
·
7 min read
FDA

Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1

Designation Based on Phase 2 SPRINT Trial in Pediatric Patients with NF1 Plexiform Neurofibromas

April 1, 2019
·
7 min read
FDA

Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1

Designation based on Phase II SPRINT trial in pediatric patients with NF1 plexiform neurofibromas

April 1, 2019
·
5 min read